Examining Eosinophil Function in Lung Diseases
The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases Based on Flow Cytometry Analysis
This study is trying to see how different types of eosinophils in the blood behave in people with certain lung diseases to help improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06944418 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with eosinophilic pulmonary diseases, such as eosinophilic granulomatosis with polyangiitis and idiopathic hypereosinophilic syndrome. It aims to identify different eosinophil subtypes in peripheral blood by analyzing surface protein expression. The study seeks to understand how these subtypes vary among patients with different eosinophilic conditions, which may help guide treatment decisions in the future.
Who should consider this trial
Good fit: Ideal candidates include patients with persistent eosinophil counts greater than 1500 per cubic millimeter and no secondary causes of eosinophilia.
Not a fit: Patients with concurrent pulmonary infections, malignancies, or other significant lung diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more targeted and effective treatments for patients with eosinophilic pulmonary diseases.
How similar studies have performed: While this approach is focused on eosinophil subtypes, similar studies have shown promise in understanding eosinophilic conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * For Healthy Volunteers: healthy volunteers matching the age and gender of the study subjects * For EPD: ① Persistent eosinophil count increase\>1500 per cubic millimeter for more than 6 months. ② Lack of evidence of a secondary cause of eosinophilia is required. ③ Signs and symptoms of end-organ damage presumed to be secondary to eosinophilia Exclusion Criteria: * Patients with concurrent definitive pulmonary infections, malignancies, or other parenchymal lung diseases; * Patients who are unable or unwilling to cooperate with the collection of clinical information (e.g., due to mental disorders, memory impairments, etc.); * Patients who are unable to provide informed consent.
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Juhong Shi, M.D
- Email: shijh@pumch.cn
- Phone: +8613701178492
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.